Inside HELP Stock's Make-or-Break Q4 Trial
Helus Pharma (HELP) stock analysis: 71% remission rate signals something big — buy or sell? 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends In this deep dive, we break down Helus Pharma (HELP) and the critical upcoming Phase 3 APPROACH trial readout in Q4 2026 for its lead psychedelic antidepressant candidate, HLP003. With $204 million in pro-forma cash providing a 1.5-year runway, the key question for investors is whether this binary clinical…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.